As controversy surrounding the COVID-19 pandemic gets dredged up again following a wave of renewed governmental scrutiny, ...
In U.S. patients with MDD, a 42 mg daily dose of Caplyta (lumateperone) as an adjunctive therapy provided a 4.5-point ...
Many overweight patients feel misunderstood by pharmas and not adequately represented in ads: survey
A significant proportion of overweight or obese patients don’t find pharmaceutical ads about weight-management products ...
Barnstorming GLP-1 drugs have sent Eli Lilly and Novo Nordisk rocketing up the list of the most valuable pharma brands. The ...
Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval
The world’s best-selling medicine is still adding new uses, and its latest FDA approval marks a first in the cancer ...
While AstraZeneca’s Truqap bears the distinction of being the first AKT inhibitor to pass muster with the U.S. | In the ...
Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. | Physicians have ...
The leading companies were once again not pharmas but instead medical technology firms, with Siemens Healthineers taking the ...
Aerovate Therapeutics’ attempt to use an inhaled formulation of Novartis’ cancer med Gleevec as a treatment for pulmonary ...
On Monday, Marinus revealed that the phase 3 RAISE trial testing ganaxolone, which is an intravenous (IV) formulation of its ...
The FDA has approved the world’s first pneumococcal disease vaccine designed for adults, signing off on Merck’s Capvaxive (formerly V116) and positioning it to become the primary shot used by seniors ...
A whistleblower case dating back to 2012 culminated in a $150 million guilty verdict for Johnson & Johnson after a New Jersey ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results